The cancer-fighting potential hidden inside a popular fitness supplement

For decades, creatine has been synonymous with bodybuilders, athletes, and those looking to preserve muscle mass. But new research suggests the familiar supplement may have another, far more intriguing role: helping the immune system fight cancer. ^[][]

The findings, published in iScience by investigators at UCLA, don’t suggest that oncologists should start recommending creatine to every patient, but it does raise an important question: Could a cheap, widely available nutritional supplement eventually become an adjunct to immunotherapy?

A new target: The dendritic cell

Much of modern immuno-oncology has focused on T cells. This study instead turns attention upstream to dendritic cells—the antigen-presenting cells responsible for activating cytotoxic T cells in the first place.

When investigators genetically eliminated creatine transport in mouse dendritic cells, immune activation faltered. Antigen presentation weakened, fewer tumor-specific CD8+ T cells were activated, and antitumor immunity declined.

Conversely, creatine supplementation produced the opposite effect. In melanoma mouse models, supplemental creatine increased dendritic-cell activation, enhanced T-cell responses, and significantly slowed tumor growth. ^[][]

Laboratory experiments using human monocyte-derived dendritic cells demonstrated similar improvements in activation, suggesting the biology may translate beyond mice.

Why oncologists should care

Checkpoint inhibitors rely on functional T-cell responses. Cancer vaccines depend on effective antigen presentation. Dendritic-cell therapies require robust dendritic-cell activation.

If creatine improves dendritic-cell fitness inside nutrient-depleted tumors, it could theoretically enhance each of those strategies.

Rather than acting as an anticancer drug itself, creatine may ultimately prove useful as an immune-supportive adjunct, improving the effectiveness of existing therapies.

A popular supplement with a new role in cancer care?

Creatine is hardly new to medicine. Clinicians have long recognized its role in skeletal muscle energetics, and it has been studied extensively for improving muscle mass, performance, and recovery. ^[]

In oncology, interest has largely centered on whether supplementation might help mitigate cancer-related muscle loss or cachexia.

That clinical experience has produced mixed results. One randomized trial involving patients with cancer cachexia failed to demonstrate meaningful improvements in weight gain, strength, quality of life, or survival compared with placebo. ^[]

This new work represents a different paradigm entirely. Rather than targeting skeletal muscle, investigators are targeting immune-cell metabolism.

Not every study points in the same direction

The excitement surrounding these findings should be balanced with an important caveat: Creatine biology in cancer is complex.

Research suggests that creatine can enhance antitumor immune responses, but creatine metabolism may also promote invasion or metastasis in certain tumor settings, including colorectal, pancreatic, and breast cancers. ^[]

The relationship appears to depend on tumor type, cellular context, and whether creatine acts within immune cells or in tumor cells themselves.

In other words, creatine is unlikely to become a universal recommendation across oncology. Instead, future studies will need to identify which cancers—and which treatment regimens—might benefit from metabolic immune support.

Although patients may see headlines suggesting that creatine “fights cancer,” this study does not justify routine supplementation during active treatment.

The next steps will require carefully designed human clinical trials to determine whether the immune effects observed in mice translate into better responses to checkpoint inhibitors, cancer vaccines, adoptive cellular therapies, or other immunotherapeutic approaches.